Skip to content
Research/Gene Therapy/AAV9-Follistatin Gene Therapy

AAV9-Follistatin Gene Therapy

compound

preliminary evidencePublic

AAV9-Follistatin gene therapy involves using an adeno-associated virus (AAV9) vector to deliver the follistatin gene into cells. Follistatin is a protein that inhibits myostatin, a growth factor that limits muscle growth. This therapy aims to enhance muscle mass and strength, which could be beneficial for age-related muscle loss and other muscle-wasting conditions, contributing to improved longevity and healthspan.

Category: Gene TherapyUpdated 8/5/2026

Intelligence Profile

Overview

AAV9-Follistatin Gene Therapy is an experimental treatment that uses a viral vector, specifically the adeno-associated virus serotype 9 (AAV9), to deliver the follistatin gene into the body. Follistatin is a protein known to inhibit myostatin, which is involved in regulating muscle growth. By increasing follistatin levels through gene therapy, researchers aim to enhance muscle mass and strength, which can counteract age-related muscle loss, also known as sarcopenia.

This therapy is significant for longevity and health optimization because maintaining muscle mass as we age is crucial for preserving mobility, balance, and overall vitality. Sarcopenia can lead to increased frailty, a higher risk of falls, and a decreased quality of life. By potentially reversing or slowing muscle deterioration, AAV9-Follistatin Gene Therapy could help prolong functional independence in older adults, thus improving health outcomes and possibly extending healthy lifespan.

It's important to note that while this therapy shows promise, it is still in the early stages of clinical trials, with studies like CALM-AF-AI currently recruiting participants. Ongoing research is necessary to establish its safety and efficacy fully.

Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice, diagnosis, or treatment.

Biohacker actions
Check interactionsView protocols

Deep dive

Intelligence Profile

AI-EnrichedUpdated Aug 5, 2026

The Science

Currently, there is insufficient evidence provided specifically about the AAV9-Follistatin Gene Therapy to describe its mechanism of action. No relevant studies or data directly address how this gene therapy works at a molecular or physiological level.

For detailed clinical decisions, it’s important to consult additional specialized publications or clinical trial results specific to AAV9-Follistatin.

Disclaimer: This information is not intended to serve as medical advice. For personal health concerns, please consult a healthcare professional.

Clinical Applications

Currently, there is limited specific evidence on AAV9-Follistatin Gene Therapy applications from the provided references. However, there is a clinical trial (NCT ID: NCT07443826) indicating that this therapy is being investigated for its potential to counteract age-related muscle loss. This study is in the recruitment phase and combines AAV-Follistatin with an angiogenesis-inducing VEGF plasmid gene therapy to explore its effects on muscle preservation and regeneration.

The evidence provided lacks direct findings specific to AAV9-Follistatin, suggesting that ongoing and future research is required to better understand its clinical applications and effectiveness.

Disclaimer: This is a general overview and should not be taken as medical advice. Always consult healthcare professionals for specific medical recommendations.

Safety Profile

Currently, there is no specific safety profile information provided for AAV9-Follistatin Gene Therapy based on the evidence available. None of the studies or articles listed directly address the safety, side effects, contraindications, or interactions for this therapy.

Given the recruiting status of the clinical trial NCT07443826, it seems that research into this gene therapy is ongoing, likely indicating that comprehensive safety data might still be under development. Generally, gene therapies require careful assessment of immune responses, long-term effects, and potential integration into the host genome, but specific data for AAV9-Follistatin are not available in the provided material.

In clinical trials, possible side effects and contraindications are typically monitored closely, but detailed findings would be necessary for a conclusive safety profile.

Thus, further evidence is needed to outline detailed safety information for AAV9-Follistatin Gene Therapy. Until more specific trial results are published, practitioners and patients should proceed with caution.

Disclaimer: This content is for informational purposes and not a substitute for professional medical advice. Always consult healthcare providers for personal medical decisions.

Key Research Papers

Currently, there are no specific research papers directly addressing "AAV9-Follistatin Gene Therapy" in the provided evidence. However, a relevant clinical trial, NCT07443826, is focused on addressing age-related muscle loss using AAV-Follistatin combined with a VEGF plasmid gene therapy. This trial is still in the recruiting phase and spans Phase 1 and Phase 2, suggesting it is in early stages of human testing to evaluate safety and preliminary efficacy.

Since no other studies or trials directly targeting this gene therapy were included in the provided evidence, further conclusions or details specific to AAV9-Follistatin Gene Therapy cannot be drawn from this dataset. It is important to consult broader scientific and clinical databases or literature for more comprehensive information.

Disclaimer: This content is for informational purposes only and not a replacement for professional medical advice.

Clinical Protocols

Current evidence does not provide specific dosing or administration protocols for AAV9-Follistatin gene therapy. The listed clinical trials, such as NCT07443826, are still recruiting, indicating that protocols may be under investigation or not publicly detailed yet.

For detailed and personalized medical advice, consulting a healthcare professional is essential. Always discuss treatment options with your healthcare provider before making any medical decisions.

Disclaimer: This information is for educational purposes only and is not intended as medical advice.

Outcomes & Evidence

Currently, there are no specific published outcomes for "AAV9-Follistatin Gene Therapy" reported in the provided literature. None of the listed studies or trials directly addresses the outcomes of this therapy. The only relevant clinical trial (NCT07443826) is still in the recruiting phase, indicating that results or outcomes have not yet been published. As such, there is no available data on measurable results such as biomarker changes or symptom improvement related to AAV9-Follistatin Gene Therapy in the evidence provided.

Disclaimer: This summary is for informational purposes only and is not intended as medical advice. Always consult a healthcare provider for advice on medical treatments.